1. Home
  2. NOM vs ABP Comparison

NOM vs ABP Comparison

Compare NOM & ABP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NOM
  • ABP
  • Stock Information
  • Founded
  • NOM 1993
  • ABP 2004
  • Country
  • NOM United States
  • ABP United States
  • Employees
  • NOM N/A
  • ABP N/A
  • Industry
  • NOM Investment Managers
  • ABP Biotechnology: Pharmaceutical Preparations
  • Sector
  • NOM Finance
  • ABP Health Care
  • Exchange
  • NOM Nasdaq
  • ABP Nasdaq
  • Market Cap
  • NOM N/A
  • ABP 12.1M
  • IPO Year
  • NOM N/A
  • ABP N/A
  • Fundamental
  • Price
  • NOM $11.00
  • ABP $0.19
  • Analyst Decision
  • NOM
  • ABP Strong Buy
  • Analyst Count
  • NOM 0
  • ABP 1
  • Target Price
  • NOM N/A
  • ABP $4.00
  • AVG Volume (30 Days)
  • NOM 6.9K
  • ABP 696.2K
  • Earning Date
  • NOM 01-01-0001
  • ABP 05-18-2025
  • Dividend Yield
  • NOM 3.39%
  • ABP N/A
  • EPS Growth
  • NOM N/A
  • ABP N/A
  • EPS
  • NOM N/A
  • ABP N/A
  • Revenue
  • NOM N/A
  • ABP $183,000.00
  • Revenue This Year
  • NOM N/A
  • ABP N/A
  • Revenue Next Year
  • NOM N/A
  • ABP N/A
  • P/E Ratio
  • NOM N/A
  • ABP N/A
  • Revenue Growth
  • NOM N/A
  • ABP 50.00
  • 52 Week Low
  • NOM $8.52
  • ABP $0.23
  • 52 Week High
  • NOM $10.48
  • ABP $13.00
  • Technical
  • Relative Strength Index (RSI)
  • NOM 67.63
  • ABP N/A
  • Support Level
  • NOM $10.50
  • ABP N/A
  • Resistance Level
  • NOM $10.94
  • ABP N/A
  • Average True Range (ATR)
  • NOM 0.22
  • ABP 0.00
  • MACD
  • NOM 0.14
  • ABP 0.00
  • Stochastic Oscillator
  • NOM 100.00
  • ABP 0.00

About ABP Abpro Holdings Inc Common Stock

Abpro Holdings Inc is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. It is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its proprietary DiversImmune and MultiMabTM antibody discovery and engineering platforms. The company is developing a pipeline of next-generation antibodies, both independently and through collaborations with pharmaceutical and research institutions.

Share on Social Networks: